New York 2025-2026 Regular Session

New York Senate Bill S04676

Introduced
2/11/25  
Refer
2/11/25  

Caption

Adds xylazine to the depressants designated as controlled substances with the exception of use in cattle or other nonhuman species if approved by the federal food and drug administration.

Summary

Bill S04676 seeks to amend the public health law in New York by adding xylazine to the list of controlled substances classified as depressants. The bill specifies that any individual who possesses, sells, administers, prescribes, or distributes xylazine for human consumption will face penalties similar to those for other controlled substances. However, it allows for the use of xylazine in cattle or other nonhuman species, provided that such use is approved by the federal Food and Drug Administration (FDA). This distinction aims to regulate the substance's use in humans while permitting its legitimate veterinary applications.

Impact

The passage of this bill would result in xylazine being classified as a controlled substance under New York state law, thereby imposing legal restrictions on its use in humans. This change aims to curb the misuse of xylazine, which has been associated with increasing rates of overdose and health risks. The bill would align state law with federal regulations regarding controlled substances and enhance public health safety by preventing unauthorized human consumption of xylazine.

Sentiment

The sentiment surrounding Bill S04676 appears to be generally supportive among legislators, reflecting a growing concern over the misuse of xylazine and its implications for public health. While there have been no recorded votes or formal committee discussions available, the introduction of the bill by multiple senators suggests a collaborative effort to address the issue of substance abuse in the state.

Contention

Notable points of contention may arise regarding the balance between regulating xylazine for human use and allowing its use in veterinary medicine. Some stakeholders may argue that stringent regulations could hinder legitimate veterinary practices, while others may emphasize the need for strict controls to prevent human misuse. The bill's supporters likely include public health advocates, while potential opposition may come from veterinary professionals concerned about the implications for animal care.

Companion Bills

NY A05099

Same As Adds xylazine to the depressants designated as controlled substances with the exception of use in cattle or other nonhuman species if approved by the federal food and drug administration.

Previously Filed As

NY A05099

Adds xylazine to the depressants designated as controlled substances with the exception of use in cattle or other nonhuman species if approved by the federal food and drug administration.

NY HB1881

Adds xylazine to the list of Schedule III controlled substances

NY HB0077

CONTROLLED SUB-XYLAZINE

NY SB465

classifying xylazine as a schedule III controlled drug.

NY SB1724

Makes xylazine a Schedule III controlled substance

NY SB866

Further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.

NY SB3221

CONTROLLED SUB-XYLAZINE

NY HB417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

NY HB0417

Criminal Law - Schedule III Controlled Dangerous Substances - Medetomidine and Xylazine

NY HB2828

Adds certain psychoactive substances to the list of Schedule I controlled substances and modifies the offenses of possession of a controlled substance and delivery of a controlled substance

Similar Bills

No similar bills found.